Genmab — September 2018
-
https://finance.yahoo.com/news/why-bluebird-celgene-worry-amgen-141500228.html
Først Amgens imponerende resultater med bite bispecific. -
Vil lige ønske alle en god weekend og gøre opmærksom på at recepttallene for USA formentligt lander allerede på onsdag som jeg kan regne det ud (den første onsdag efter den 3 lørdag i md). Det er altså den 19/9 !
-
"In conclusion, the combination of daratumumab, lenalidomide, and dexamethasone may currently be the most effective regimen in the population of RRMM patients." https://www.oncologynurseadvisor.com/navigator-notes/triplet-regimen-found-most-effective-for-rrmm/article/795972/ https://www.dovepress.com/treatment-options-for-refractoryrelapsed-multiple-myeloma-an-updated-e-peer-reviewed-fulltext-article-CMAR
-
Kinase inhibitor advances in MM: predictive biomarkers & efficacy of daratumumab https://www.vjhemonc.com/video/m_o9uyu8d00-kinase-inhibitor-advances-in-mm-predictive-biomarkers-efficacy-of-daratumumab/
-
Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management - Vincent Rajkumar - https://onlinelibrary.wiley.com/doi/10.1002/ajh.25117
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind